[A18-65] Sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to § 35a Social Code Book V (expiry of the decision)

Last updated 02.01.2019

Project no.:

Commission awarded on 28.09.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Commission completed

Drug Assessment

Application field:
Digestion, metabolism and hormones


Adult patients with type 2 diabetes mellitus with inadequate glycaemic control by diet and exercise plus metformin monotherapy

Result of dossier assessment:

Comparison with sulfonylurea (glibenclamide or glimepiride) + metformin: hint of non-quantifiable (at most considerable) added benefit. Comparison with glipizide + metformin: treatment goal near-normal blood glucose levels: hint of considerable added benefit; other treatment goal: added benefit not proven


After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2019-07-04 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.